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Abstract: N,N-Dimethylacetamide (DMA) is FDA approved as an excipient and is used as
drug-delivery vehicle. Due to its amphipathic nature and diverse bioactivities, it appears to
be a good combination of biodegradable poly-lactide-co-glycolide (PLGA)-based guided bone
regeneration membranes. Here we show that the solvent DMA can be loaded to PLGA membranes
by different regimes, leading to distinct release profiles, and enhancing the bone regeneration
in vivo. Our results highlight the potential therapeutic benefits of DMA in guided bone regeneration
procedures, in combination with biodegradable PLGA membranes.
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1. Introduction
Guided bone regeneration (GBR) is a procedure used frequently in dentistry to restore alveolar
deficiencies and to prepare the site for the placement of dental implants [1]. The rationale for
applying a membrane is to prevent the ingrowth of non-osteogenic tissues into the space where
bone formation should occur [2]. The membrane can be applied with or without bone substitute
materials [3,4]. In the first case, the membrane, in addition to installing compartmentation, prevents
granular bone substitutes from dispersion. Since the time when guided bone regeneration by
membranes was established, a multitude of materials were tested [5–7]. Originally, the non-resorbable
expanded polytetrafluorethylen (ePTFE) membranes, and more recently the resorbable native collagen
membranes, are used most frequently [8].
The switch from non-resorbable membranes to resorbable membranes changes the clinical
procedure substantially, since it obviates the need for a second surgery to remove the non-resorbable
material. This feature also distinguishes the first generation, non-resorbable from the resorbable second
generation membrane [9]. The third generation of GBR membranes that are not only occlusive and
resorbable, but also exert bioactivity to biologically stimulate osteoprogenitor cells for enhanced bone
growth, was achieved more than a decade ago by the combination of a poly-lactide-co-glycolide (PLGA)
membrane with the plasticizer N-methyl-pyrrolidone (NMP) [10]. From the broad spectrum of NMP’s
bioactivities, NMP released by the membrane appeared attractive for guided bone regeneration. NMP’s
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bioactivities encompass the enhancement of the activity of bone morphogenetic proteins (BMPs) [11],
inhibition of osteoclast formation and activity [12], facilitation of bone regeneration in inflamed
states [13,14], and reduced bone loss under osteoporosis [15]. Despite all these advantageous activities,
the performance of the NMP-releasing PLGA membrane in clinical trials was not superior when
compared to the more established resorbable and non-resorbable membranes [16,17]. More recent work
on the applications of NMP and BMP for sinus lifts yielded inconsistent effects on bone regeneration,
resulting in no significant benefits compared to controls [18]. Taken together, the usage of the organic
solvent NMP as a drug delivered by bone substitutes or GBR membranes failed so far to be translated
into the clinic.
Organic solvents are commonly used in the pharmaceutical industry as reaction media, for
product synthesis, and as drug vehicles. N,N-Dimethylacetamide (DMA) is FDA approved as an
excipient and therefore widely used as a drug-delivery vehicle [19]. In high-risk neuroblastoma
treatment, for example, DMA, at a high concentration, is administered to facilitate chemotherapy by
busulfan [20]. In 2013, Reznik and co-workers found DMA to be bioactive [21]. We showed that DMA
binds bromodomains, and is thus epigenetically active in bone regeneration, bone degradation, and
osteoporosis [22]. In conjunction with guided bone-regeneration procedures, its ability to enhance
bone regeneration and to inhibit bone destruction by osteoclasts [22] could be beneficial.
Here we report how a PLGA-based membrane can be loaded with DMA, and how the loading
regime affects the surface of the membrane and the release of DMA. Moreover, we performed a
preclinical test of a DMA-loaded PLGA membrane in a GBR membrane model in the rabbit calvaria.
2. Materials and Methods
2.1. Chemical Loading of PLGA Membranes
N,N-Dimethylacetamide (DMA) anhydrous with 99.8% purity (Sigma-Aldrich Chemie GmbH, St.
Gallen, Switzerland) was used for the experiments. PLGA membranes (Inion GTRTM membranes,
Inion Oy, Tampere, Finland, 30 × 40 mm; 0.2 mm thick) were loaded with pure DMA by two different
techniques: (1) a vapor deposition method and (2) direct dipping into the liquid chemical. Membranes
were loaded to reach a weight gain of 10%, 25%, and 50%; hereafter named vapor 10%, vapor 25%,
and vapor 50%. Vapor deposition was performed at room temperature in a desiccator connected to
a vacuum pump. Inside the desiccator, the membranes were placed onto a metal mesh laying over
a glass dish filled with pure DMA. To assess the weight gain of the membranes during the loading
protocol, membranes were weighed before, during, and after vapor deposition on a chemical balance,
and vapor deposition was allowed until intended loading percentage was reached. For 50% loading,
the procedure took 22 h. Dip loading of the membrane to 50% was achieved by dipping the PLGA
membrane into pure DMA for 10 s.
2.2. In Vitro Release of Chemicals
The release experiment was performed in triplicate. Equal-sized, chemical-loaded membrane
samples were placed into glass bottles containing 50 mL of phosphate-buffered saline (PBS, pH 7.4).
For the time course of the in vitro release, samples were kept agitating at 37 ◦C. At indicated time
points (2 min up to 16 weeks), 200 µL of sample was removed and stored at 4 ◦C for subsequent
analysis. DMA concentration was measured at 220 nm, using 96-well plates coated to enable reading
at UV wavelengths (Corning, Corning, NY, USA). Values were compared to a standard curve of known
DMA concentrations. To estimate the non-toxic concentration of the released DMA for the in vivo
experiments, the membrane surface and release volume were taken into consideration.
2.3. Scanning Electron Microscopy for Structural Analysis
Chemical-loaded membranes were air-dried, fixed onto metal stubs, and gold-coated using a gold
sputter machine (SCD 030, Baltec, Balzers, Lichtenstein). Parameters applied for sputtering and leading
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to a gold layer thickness of about 10 nm were the following: sputtering time 90 s, current 45 mA, and
distance of gold target to sample 60 mm. The membrane structure was analyzed using the Zeiss Supra
V50 SEM (Carl Zeiss, Oberkochen, Germany) at an acceleration voltage of 5 kV. Access to the SEM was
kindly provided by the Center for Microscopy and Image Analysis (ZMB) at the University of Zürich.
2.4. Animal Model for Guided Bone Regeneration
All animal experiments were approved by the local authorities (Veterinäramt Zurich, Switzerland)
under the licenses: 108/2012 and 115/2015. Six New Zealand white rabbits were used in this experiment.
To initiate the operation, the animals were anesthetized by an injection of 65 mg/kg ketamine and
4 mg/kg xylazine, and maintained under anesthesia with isoflurane/O2. Opening of the soft tissue
was followed by removal of the periosteum. Four defects of 6 mm in diameter were marked on each
animal’s skull halfway into the cranial bone, using a trephine fixed in a dental hand piece. Defect
areas were kept clean from bone debris by constant flushing with 0.9% saline solution. The creation of
defects was completed using a round burr. For the guided bone regeneration method, one piece of the
membrane, 7 mm in diameter, was pushed inside the defect and fixed in place by the intrinsic pressure
of the brain and the dura mater. The second piece was placed on top of the defect, fixed by two titanium
pins to allow for an empty space between the two membranes where the bone could regenerate in a
guided manner as reported earlier [23]. One of the four defects was kept empty to serve as a control
for non-treated bone regeneration and was termed empty control. A second defect was closed with
untreated PLGA membranes not loaded with DMA, and one defect was treated with vapor 10% DMA
membranes. The fourth defect was treated with a membrane loaded with an exploratory substance,
which is not part of this study. The treatment modalities of the four defects were assigned randomly
for the first animal. For the consecutive animals, the modalities were rotated clockwise by one defect.
After treating the defects, soft tissues were closed by sutures and animals received analgesia specified
in the license. Four weeks after surgery, the animals were sedated using barbiturates and an overdose
of ketamine for sacrifice. Calvarial bones were excised and immediately processed for histology.
2.5. Histology
Excised calvarial bone samples were fixed with 70% ethanol, and dehydrated using a sequential
water substitution process at 24 h in 40% ethanol, 72 h in 70% ethanol (solution replaced every 24 h),
72 h in 96% ethanol and a final dehydration step for 72 h in 100% ethanol (solution replaced every
24 h). Fixation and defatting were allowed for 72 h in xylene (solution replaced every 24 h). Plastic
infiltration was performed using methyl methacrylate (MMA, Sigma M55909) for one week at 4 ◦C.
Samples were then embedded in MMA containing 0.5% Perkadox 16 (Dr. Grogg Chemie AG, Stettlen,
Switzerland, G425), 15% dibuthylthalate (Sigma-Aldrich, St. Louis, MO, USA, 524980), and 0.01%
Pentaerythritol tetrakis (Sigma-Aldrich 441783) for 72 h at 4 ◦C. Polymerization was continued for 48 h
at 26 ◦C and through subsequent temperature increases over 1 week to 37 ◦C (bench top incubator with
air supply, Memmert, Scharbach, Germany) while constantly checking for polymerization progress.
Fully polymerized samples were cut using a Mecatome T180 (Presi, Le Locle, Switzerland) and further
processed to 10 µm sections (Leica Reichert Jung Polycut S, Austin, TX, USA). Sections from the middle
of the samples were stained using the Goldner’s Trichrome method. Images were acquired using a
Leica microscope with a millimeter scale and were analyzed using the Adobe Photoshop program.
2.6. Statistical Analysis
All statistical analyses were performed with IBM SPSS statistics 25. Results are expressed as
the mean ± SD and were compared by the non-parametric Kruskal–Wallis test followed by the
Mann–Whitney U test. Results were considered significantly different for p < 0.05.
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3. Results
3.1. Loading of Membranes with DMA
To utilize the PLGA-based guided bone regeneration membrane, we first studied the uptake of
DMA via vapor deposition, where a membrane is subjected for different time intervals to DMA vapor.
Loading the membrane with 10 wt % DMA is achieved within 2 h. A 25 weight percentage loading
needs 5 h, and 50 weight percentage loading 22 h, respectively (Figure 1).
Figure 1. Vapor deposition of N,N-Dimethylacetamide (DMA). Vapor deposition up to 22 h is presented.
A total of 1320 min are needed to reach 50 wt % DMA loading. Black diamonds indicate loading for
the vapor 10% sample, which needs 120 min. The dark grey squares represent the vapor 25% sample,
needing 300 min. Light blue triangles depict the loading curve for the vapor 50% sample.
When dipped in pure DMA it takes only 10 s for the uptake of DMA to reach 50 weight
percentage. Since DMA is a volatile substance, upon loading the DMA membranes had to be stored in
a closed compartment.
3.2. DMA Release from Membrane
The storage of the vapor 50%-loaded membranes in air led to a decrease in the DMA-load by 20%
of the original loading over a four-day period. The dip-loaded membranes lost 90% of their DMA in
the first 5 h after exposure to air. Therefore, the storage and eventual distribution of loaded membranes
could cause problems.
Next, we performed release studies of loaded membranes in PBS to mimic the in vivo situation.
Released DMA was assessed for each time point individually while the collected sample volumes were
taken into account (Figure 2). Clear differences between the release kinetics exist between all of the
differentially treated membranes. While the vapor 10% membranes released their contained chemical
gradually over multiple hours, the dip-loaded membrane released almost all DMA within the first few
minutes, reaching a plateau phase at 80% within 30 min. All other membranes reached this plateau
phase, which approached the 100% release mark, during the measuring period at four months.
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Figure 2. In vitro release of DMA from membranes, within forty-eight hours of measurement. Loading
patterns are as follows: black diamond, DMA vapor exposure to 10 wt %; grey squares, vapor to
25%; blue triangle, vapor to 50%; red squares, dip-loaded to 50%. Total release of all the contained
chemical into the PBS solution is referred to as 100% release. Individual values for each time point are
represented as a percentage of maximal possible release or “cumulative release”.
3.3. Impact on Membrane Structure
These release kinetics indicated a difference between the two protocols for loading the membranes.
A difference in appearance was observed right after the loading of the chemical. The dip-loaded
membrane “dip 50%” (d50) turned opaque and rigid shortly after loading, in contrast to the vapor-loaded
membranes, which stayed transparent and flexible after loading with DMA. To further investigate
the effect of the different methods of chemical loading onto the structure of the membranes, scanning
electron microscopy (SEM) was performed. A non-treated membrane served as a control for the initial
membrane surface morphology (Figure 3).
3.4. In Vivo Experiment with a DMA-Loaded Membrane
To estimate the expected effective concentration of DMA released from the DMA-loaded
membranes into the calvaria defect rabbit model, the size of the applied membranes was set to
2× 38 mm2 and the volume enclosed by the two membranes was set to 100µL. Based on these estimations,
the calculated concentrations for all but the vapor 10% membranes exceeded 10 mM, which is toxic for
cells [22]. Therefore, only the membrane vapor 10% was chosen for the in vivo experiment.
After operation, the animals behaved normally, suggesting that the choice of the membrane vapor
10% and the released DMA had no negative effects on the well-being of the rabbits. Bone regeneration
was allowed for four weeks. After sacrifice, calvarias were collected and processed for histological
analysis. Examples of the histologies of the different treatments are presented in Figure 4.
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Figure 3. SEM images of native control and DMA-loaded membranes. Control: the surface of an
untreated, native membrane is displayed at 20,000×magnification. (A–D) Images at 5000×magnification
(white scale bar in A represents 2 µm for the entire column), (E–H) images at 20,000×magnification
(white scale bar in E represents 1 µm for the entire column).
The histomorphometric analysis (Figure 5), based solely on the middle section from the
defect, showed that the bony bridging achieved by the application of the vapor 10% membrane
(100.00 ± 0.00%) was significantly higher than compared to the empty control defect (52.78 ± 34.49%)
(p < 0.015). No significant difference was seen with the native PLGA membrane (membrane no
DMA) (75.00 ± 33.33%), neither compared with the empty control defect or with the vapor 10%
DMA-loaded membrane (membrane vapor 10%). The bony regenerated area achieved with the vapor
10% DMA-loaded membrane (membrane vapor 10%) (70.93 ± 17.04%) was, however, significantly
higher than the empty control defect (21.71 ± 12.22%), and the defect treated with unloaded membrane
(membrane no DMA) (32.21 ± 24.51%).
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Figure 4. Goldner’s Trichrome staining of calvarial defects treated with poly-lactide-co-glycolide
(PLGA)-based membranes (A) empty control defect, (B) defect treated with two native PLGA membranes
(membrane no DMA), (C) defect treated with two PLGA membranes loaded to 10 wt % with DMA
(membrane vapor 10%). M marks the transparent layer of the membranes placed above and below the
defect. Black arrows indicate the defect width of six mm. Trichrome stains the bone in a greenish-blue
color and the osteoid in red.
Figure 5. Analysis of bone regeneration parameters. (A) Quantification of bony bridging represented as
a percentage of the 6 mm defect, (B) bony regenerated area as a percentage of pixel numbers identified
as bone in the trichrome staining in relation to the entire defect. Empty refers to the defects without any
membrane. Membrane no DMA refers to the native PLGA membranes. Membrane vapor 10% refers to
the PLGA membranes pre-loaded with 10 wt % DMA via vapor deposition. Values are displayed as
box plots ranging from the 25th (lower quartile) to the 75th (upper quartile) percentile, including the
median as a solid black line and whiskers showing the minimum and maximum values. In (B) values
outside the range of the box plot are shown as individual points. (p values are provided).
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4. Discussion
The evolution of guided bone regeneration membranes has gone from barrier membranes
to biodegradable barrier membranes to bioactive biodegradable barrier membranes [9]. Here we
characterize a guided bone regeneration membrane of the third generation, which serves as barrier, is
biodegradable, and is bioactive due to the release of DMA.
DMA is an FDA-approved excipient and is used as a solvent in diverse formulations of drugs [19,24].
Despite its clinical use as an excipient, its diverse activities have been overlooked for many years [21].
More recently, we have identified the underlying mechanism for all these diverse and beneficial
activities. DMA binds bromodomains, based on the low affinity of DMA for this acetyl-residue-binding
site [22]. Since bromodomains are an important element to assemble the machinery for NF-kappa-B
transcription [25], DMA significantly attenuates lipopolysaccharide- and tumor necrosis factor-induced
proinflammatory responses [26]. In conjunction with guided bone regeneration, a reduction in
inflammation could be beneficial, and so would the enhancement of the activity of bone morphogenetic
protein signaling, and the inhibition of osteoclast differentiation and activity [22]. This notion proved
true in our in vivo experiments, where the DMA-loaded membrane performed significantly better
in terms of bony bridging than the control (Figure 5). Even more striking was the performance of
the DMA-loaded membrane in the extent of bony regeneration for the defect area. In this aspect, the
DMA-loaded membrane performed significantly better than the native membrane and the control.
Therefore, local and sustained release of DMA is beneficial in conjunction with guided bone regeneration
procedures. Nevertheless, more studies in larger animals, in alveolar bone models, and with additional
time points are needed to further substantiate this finding.
The major problem utilizing DMA as a drug is achieving a sustained delivery of dosages in the
millimolar range, since its affinity to bromodomains is in this range [22]. Therefore, we tried the vapor
deposition methodology, which we have used before to load membranes with N-methyl pyrrolidone
(NMP) [27], another FDA-approved excipient. In essence, we achieved very similar results to what we
did with NMP and selected the vapor 10% loaded membrane for the in vivo test. The two reasons
were, firstly, that the vapor 10% membrane provides the most sustained DMA delivery in a non-toxic
range (Figure 2). Secondly, the structure and integrity of the membrane was preserved the most with
this loading regime (Figure 3).
By combining a PLGA membrane with DMA, we developed another guided bone regeneration
membrane of the third generation. DMA added bioactivity to the system, as evidenced by the increased
bony regeneration and bony bridging (Figure 5). In the direct comparison of bony regeneration
vapor 10% NMP, another FDA-approved excipient reached 67.10 ± 10.54% [1] and vapor 10% DMA
(70.93 ± 17.04%). For bony bridging, vapor 10% NMP reached 89.24 ± 14.34% and vapor 10% DMA
100.00 ± 0.00%. Both excipients, NMP and DMA, appear to have a similar potency in terms of bone
regeneration and bony bridging, but the lower volatility of NMP makes it more suitable for carrier
systems like the PLGA membrane. For systemic applications via injections, however, DMA has been
used very successfully in clinical and preclinical trials [19,21,22,28].
More advanced in the field of guided bone regeneration research is the application of NMP. For
the NMP-loaded membrane, the dip-loaded version was used for preclinical [11,29] and two clinical
trials [16,17]. Unfortunately, in both clinical trials the dip-loaded NMP-releasing membrane was only
equal to (but failed to outperform) clinically well-established membranes. Whether a membrane
with NMP deposited by vapor could lead to better results in humans has not been tested yet. In a
preclinical trial, however, the vapor 10% NMP performed significantly better than the dip-loaded
NMP membrane [27]. Furthermore, calcium phosphate-based bone substitutes have been tested as
delivery systems for NMP. However, in the preclinical sinus lift model, no benefits of NMP could be
detected [18].
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5. Conclusions
The local delivery of DMA in conjunction with a PLGA-based guided bone regeneration membrane
significantly enhanced bony regeneration and bony bridging, thus adding bioactivity to the system,
and turning it into a third-generation membrane. However, more research with additional and more
relevant animal models is needed to develop the ideal delivery system to maintain the relatively high
concentrations of DMA needed to exert its bioactivities efficiently over a longer period.
6. Patents
The University holds a patent on DMA in conjunction with osteoporosis.
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